SCHEMBL2407736

SCHEMBL2407736

OB(c1ccc(COCCOc2ccc(B(O)c3cccs3)cc2)cc1)c1cccs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
POLB P06746 2/20 0.34
PPARG P37231 1/20 0.34
MAPT P10636 3/20 0.32
KDM4E B2RXH2 2/20 0.32
RGS12 O14924 1/20 0.32
LTA4H P09960 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274683 0.86 TSHR (0.36) POLBKDM4E
SCHEMBL2408595 0.80 ORAI1 (0.44) APPLMNANPC1RAB9APPARG
SCHEMBL12266253 0.80 KDM4E (0.39) APPMEN1KMT2AALDH1A1KDM4E
SCHEMBL3274847 0.77 RAB9A (0.33) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL4817895 0.73 CA1 (0.49) LMNANPC1RAB9APPARGMAPT
SCHEMBL12266209 0.72 LPL (0.50) MEN1KMT2AALDH1A1HTTLMNA
SCHEMBL9478520 0.68 KCNA3 (0.56) APPALDH1A1LTA4H
SCHEMBL16320997 0.67 LMNA (0.47) LMNANPC1RAB9APPARGMAPT
SCHEMBL14083852 0.67 CHRNB2 (0.44) APPLMNANPC1RAB9APPARG
SCHEMBL4162422 0.66 LTA4H (0.52) ALDH1A1LMNAPPARGLTA4HCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 US disclosed
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 US disclosed
US-8853424-B2 Protein cross-linking inhibitor JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2014-10-07 US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 US disclosed
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212919-A1 PROTEIN CROSS-LINKING INHIBITOR BAZ2B, PRMT1, BRIX1 APP 3361/4885MEN1 3255/4885KMT2A 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.